# Moleculin Biotech, Inc. (MBRX) · Edgar & Edgarette company card

> Moleculin Biotech (MBRX) reported revenue of $0 million in FY2025, operating margin null against a -3.8% median for pharmaceutical preparations, equity 67.8% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1659617 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/MBRX) · [JSON](https://www.pops4.com/boards/company/MBRX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year -Infinity%) |
| Net margin | -Infinity% |
| Operating cash flow | −$23M |
| Capital spending | $0 |
| Free cash flow | −$23M |
| Cash | $9M |
| Long-term debt | — |
| Total assets | $22M |
| Total equity | $15M |
| Equity ÷ assets | 67.8% |
| Return on equity | -223.6% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -34.92 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative (-$22.7M in FY2025); operating loss: a margin of -Infinity% in FY2025

## Edgarette's reading

Exposure: revenue $0K (FY2025). Experience: one year on record; operating margin null, up from null. Soundness: equity 67.8% of assets, return on equity -223.6%. Credibility: four or more audited years, reasonable weight. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin null against a -3.8% median.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-09-18 ([filing](https://www.sec.gov/Archives/edgar/data/1659617/000143774926030757/0001437749-26-030757-index.htm))
- Item 5.02 Director or officer change: 1, latest 2026-10-09 ([filing](https://www.sec.gov/Archives/edgar/data/1659617/000143774926032455/0001437749-26-032455-index.htm))

## Recent filings

- 8-K · filed 2026-11-12 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1659617/000143774926036396/0001437749-26-036396-index.htm)
- 8-K · filed 2026-11-10 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1659617/000143774926036164/0001437749-26-036164-index.htm)
- 8-K · filed 2026-11-04 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1659617/000143774926034926/0001437749-26-034926-index.htm)
- 8-K · filed 2026-10-30 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1659617/000143774926034075/0001437749-26-034075-index.htm)
- 8-K · filed 2026-10-20 · 3.03 Material Modifications to Rights of Security Holders; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1659617/000143774926032969/0001437749-26-032969-index.htm)
- 8-K · filed 2026-10-16 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1659617/000143774926032762/0001437749-26-032762-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001659617.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1659617

## Cite

POPS4, Edgar & Edgarette: Moleculin Biotech, Inc. (MBRX) company card, from the company's own SEC filings, accessed 2026-11-13, https://www.pops4.com/boards/company/MBRX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.